35623-LT-Viral-DetectionV2-990x120 green

Event Overview

The COVID-19 pandemic highlights a need for the rapid development of detection strategies and assays for novel pathogens. The SARS-CoV-2 NGS Assay is a highly sensitive nucleic acid hybridization capture-based assay that detects the SARS-CoV-2 viral genome. This FDA-authorized-under-emergency-use assay combines virus-specific panels and comprehensive data analysis software and reporting capabilities to provide researchers with information on genetic variants, clade-associated variants, and phylogenetics. In this webinar brought to you by Twist Bioscience, Kristin Butcher and Mara Cuoto-Rodriguez will demonstrate the SARS-CoV-2 NGS assay technology and describe how researchers use it to detect and identify novel variants of the SARS-CoV-2 virus.

Topics to be covered

  • The end-to-end SARS-CoV-2 NGS assay workflow
  • The benefits of hybrid-capture technology and COVID-DX software
  • How Biotia’s COVID-DX pipeline determines the presence or absence of SARS-CoV-2, identifies genetic variants, estimates viral clades, and generates phylogenetic trees

  • Thursday, May 20, 2021
    12:00 - 1:30 PM Eastern Time

    Meet the speakers

    Kristin Butcher
    Senior Scientist
    Twist Bioscience

    Mara Couto-Rodriguez
    Director of Research and Development
    Sponsored by

    Register Now

    Optimizing Fluorescence-Activated Cell Sorting April 26, 2021

    You must have Javascript and Cookies enabled to access this webcast.

    Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.